QUOTE AND NEWS
StreetInsider.com  Jul 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Will+Report+Q2+Results+Aug.+6th%3B+Street+Sees+Narrower+Loss/9664128.html for the full story.
Motley Fool  Jul 15  Comment 
f Ariad continued to see high rates of Iclusig-induced serious adverse events and/or deaths amongst cancer patients in its new trials, the stock could be in serious trouble.
StreetInsider.com  Jul 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Receives+Request+for+Limited+Additional+Info+on+Iclusig+from+EMA%27s+PRAC/9656796.html for the full story.
StreetInsider.com  Jun 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Amends+Rights+Agreement+with+Computershare/9610267.html for the full story.
StreetInsider.com  Jun 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/ARIAD+Pharma+%28ARIA%29+Adds+Three+New+Vice+Presidents/9603567.html for the full story.
StreetInsider.com  Jun 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Sends+Letter+to+ISS%3B+Requests+Revision+of+Voting+Recommendation+to+Shareholder/9597149.html for the full story.
Motley Fool  Jun 13  Comment 
Fighting in Iraq caused the stock market to tumble Thursday, but these stocks had even bigger problems pulling them down.
StreetInsider.com  Jun 12  Comment 
Zalicus Inc. (NASDAQ: ZLCS) 50% HIGHER; stock gained after-hours on Wednesday. Traders discussed Phase 3 data from Epirus BOW015 for treatment of rheumatoid arthritis. (Note: On April 16th, Zalicus Inc. and Epirus Biopharmaceuticals...
TheStreet.com  Jun 12  Comment 
NEW YORK (TheStreet) -- UBS decreased its price target on Ariad Pharmaceuticals  to $7 and set a "neutral" rating. The firm noted limited near-term drivers of upside risk.  The stock was down 5.7% to $6.62 in pre-market trading on...
StreetInsider.com  Jun 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Prices+Upsized+Aggregate+%24200M+Convertible+Notes+Offering/9577474.html for the full story.




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki